Country: Canada
Language: English
Source: Health Canada
ENALAPRIL SODIUM (ENALAPRIL MALEATE); HYDROCHLOROTHIAZIDE
ORGANON CANADA INC.
C09BA02
ENALAPRIL AND DIURETICS
8MG; 25MG
TABLET
ENALAPRIL SODIUM (ENALAPRIL MALEATE) 8MG; HYDROCHLOROTHIAZIDE 25MG
ORAL
15G/50G
Prescription
ANGIOTENSIN-CONVERTING ENZYME INHIBITORS
Active ingredient group (AIG) number: 0252326001; AHFS:
APPROVED
2005-08-09
_VASERETIC® (enalapril and hydrochlorothiazide tablets) _ _Page 1 of 60 _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION VASERETIC® (enalapril and hydrochlorothiazide) Tablets 10 mg/25 mg oral Each tablet is made with 10 mg of enalapril maleate that appears as 8 mg of enalapril sodium in the tablet and 25 mg of hydrochlorothiazide. Angiotensin Converting Enzyme Inhibitor / Diuretic ORGANON CANADA INC. 16766 route Transcanadienne Kirkland, QC Canada H9H 4M7 www.organon.ca Date of Initial Authorization: Jul 4, 1990 Date of Revision: November 4, 2022 Submission Control Number: 265020 _VASERETIC® (enalapril and hydrochlorothiazide tablets) _ _Page 2 of 60 _ RECENT MAJOR LABEL CHANGES 1 INDICATIONS, 1.1 Pediatrics 06/2021 1 INDICATIONS, 1.2 Geriatrics 06/2021 4 DOSAGE AND ADMINISTRATION, 4.4 Administration 06/2021 4 DOSAGE AND ADMINISTRATION, 4.5 Missed dose 06/2021 7 WARNINGS AND PRECAUTIONS 11/2022 TABLE OF CONTENTS RECENT MAJOR LABEL CHANGES..............................................................................................2 TABLE OF CONTENTS ................................................................................................................2 PART I: HEALTH PROFESSIONAL INFORMATION .......................................................................4 1 INDICATIONS ................................................................................................................4 1.1 Pediatrics ............................................................................................................4 1.2 Geriatrics.............................................................................................................4 2 CONTRAINDICATIONS ...................................................................................................4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ..............................................................5 4 DOSAGE AND ADMINISTRATION...................................................................................5 4.1 Dosing Considerations Read the complete document